Bridgefront Capital »

Aeglea Biotherapeutics shares owned by Bridgefront Capital

Quarter-by-quarter ownership of Aeglea Biotherapeutics (SYRE) shares owned by Bridgefront Capital from 13F filings

Historical chart of Bridgefront Capital investment in Aeglea Biotherapeutics

Tip: Access up to 7 years of quarterly data

All positions including Aeglea Biotherapeutics held by Bridgefront Capital consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Aeglea Biotherapeutics by Bridgefront Capital

Quarter filed Position value Share count Share price at filing
2026-03-31 $436k 8.7k 50.44

More positions owned by Bridgefront Capital

Take-Two Interactive Software (TTWO)
TPG Com Cl A (TPG)
Constellation Brands Cl A (STZ)
Broadcom (AVGO)
Encana Corporation (OVV)
Kimberly-Clark Corporation (KMB)
Clorox Company (CLX)
Lamb Weston Hldgs (LW)
Keysight Technologies (KEYS)
EQT Corporation (EQT)
Celsius Hldgs Com New (CELH)
Amgen (AMGN)
Micron Technology (MU)
Host Hotels & Resorts (HST)
Agree Realty Corporation (ADC)

View all positions for Bridgefront Capital

Top funds holding Aeglea Biotherapeutics

FMR
BlackRock
Rtw Investments
Fairmount Funds Management
Perceptive Advisors
VR Adviser
Vanguard Capital Management
Driehaus Capital Management
State Street Corporation
Paradigm Biocapital Advisors
Commodore Capital
TCG Crossover Management
Tang Capital Management
Wellington Management Company
Capital Research and Management Company - Division 3

View all funds holding Aeglea Biotherapeutics